News

Dry eye increases susceptibility to psychiatric disorders and chronic pain syndromes, investigators reported at the 2024 AAO meeting

According to the company, in a confirmatory trial, Epioxa met pre-specified primary efficacy endpoint and exhibited positive tolerability and safety profiles through 12 months, supporting an anticipated NDA submission by the end of 2024.

The Center, which was launched in 2023, will now be named The Barry Family Center for Ophthalmic Artificial Intelligence and Human Health.

A Norwegian study demonstrates that transplant rates continue to drop over time

Gene therapy for nAMD represents significant advancements in the treatment of retinal conditions

The DOG recognised Heidelberg Engineering founder Christoph Schoess, Prof Herbert Kaufmann, and Prof Ioannis G. Pallikaris

Centricity Vision announced new ZEPTOLink enhancements, reducing treatment time by up to 60%. These updates, aimed at improving cataract surgery efficiency and control, will be showcased at the 2024 American Academy of Ophthalmology Annual Meeting in Chicago.

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON).

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME.

The DOG recognised Heidelberg Engineering founder Christoph Schoess, Prof Herbert Kaufmann and Prof Ioannis G. Pallikaris

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets.

AEYE Health will attend the American Academy of Ophthalmology (AAO) Annual Meeting, from October 18-21 in Chicago.

Meeting information to remember, including key locations and childcare options

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over inadequate screening and management, especially among Black and Hispanic youths.

This patented technology is designed to enhance the light sensitivity of a multi-characteristic opsin developed by Nanoscope as a gene therapy.

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

The European Association for Vision and Eye Research 27th EVER Congress will be held in Valencia, Spain, November 3 – 5, 2024.

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over inadequate screening and management, especially among Black and Hispanic youths.

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

The diverse list of sessions includes discussions of surgical ethics and an arts lecture about Ansel Adams

Applied Science, Inc. (ASI) is expanding its AdaptivMD chronic care workflow technology

MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.

The American Academy of Ophthalmology 2024 annual meeting features key lectures and award sessions, highlighting advancements in ophthalmology from leading experts across the field.

The Eye Care Network adds a longstanding, CME-certified conference to its live event programming

On World Sight Day, leading experts in ophthalmology look at artificial intelligence and how it could impact diagnosing and finding diseases in the future.